• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The role of GLP1 receptor agonists in adult-onset type 1 diabetes mellitus.

作者信息

Popovic Djordje S, Koufakis Theocharis, Patoulias Dimitrios, Maltese Giuseppe, Papanas Nikolaos

机构信息

Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia.

Second Propaedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

出版信息

Nat Rev Endocrinol. 2025 Jul 16. doi: 10.1038/s41574-025-01154-4.

DOI:10.1038/s41574-025-01154-4
PMID:40670682
Abstract
摘要

相似文献

1
The role of GLP1 receptor agonists in adult-onset type 1 diabetes mellitus.胰高血糖素样肽1受体激动剂在成人起病型1型糖尿病中的作用。
Nat Rev Endocrinol. 2025 Jul 16. doi: 10.1038/s41574-025-01154-4.
2
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.《美国医师学院成人 2 型糖尿病新型药物治疗：系统评价和网络荟萃分析》
Ann Intern Med. 2024 May;177(5):618-632. doi: 10.7326/M23-1490. Epub 2024 Apr 19.
3
Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.随机临床试验中钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂的获益比较：一项网状Meta分析
Minerva Cardiol Angiol. 2023 Apr;71(2):199-207. doi: 10.23736/S2724-5683.22.05900-2. Epub 2022 Feb 23.
4
Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽 1 受体激动剂对心血管和肾脏结局影响的种族、民族和地域差异：心血管结局试验的系统评价和荟萃分析。
J R Soc Med. 2024 Aug;117(8):267-283. doi: 10.1177/01410768231198442. Epub 2023 Sep 21.
5
Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.GLP1-RA 和 SGLT2-I 的依从性影响 2 型糖尿病患者的临床结局和成本。
Diabetes Metab Res Rev. 2024 May;40(4):e3791. doi: 10.1002/dmrr.3791.
6
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis.胰高血糖素样肽-1受体激动剂与心理健康：一项系统评价和荟萃分析。
JAMA Psychiatry. 2025 May 14. doi: 10.1001/jamapsychiatry.2025.0679.
7
Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health.基于肠促胰岛素的疗法：聚焦心血管-肾脏-代谢健康重大变革的最新进展
J Chin Med Assoc. 2025 Jul 3. doi: 10.1097/JCMA.0000000000001263.
8
Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis.GLP-1 受体激动剂对 2 型糖尿病合并慢性肾脏病患者心血管结局的影响：系统评价和荟萃分析。
Pharmacotherapy. 2022 Dec;42(12):921-928. doi: 10.1002/phar.2737. Epub 2022 Nov 4.
9
Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes.胰高血糖素样肽-1受体激动剂不会增加糖尿病患者上消化道内镜检查期间的误吸风险。
Clin Gastroenterol Hepatol. 2025 Apr;23(5):739-747. doi: 10.1016/j.cgh.2024.04.038. Epub 2024 May 15.
10
Perioperative GLP1-RA management and risk of aspiration in patients with diabetes undergoing fast-track hip and knee arthroplasty.接受快速康复髋膝关节置换术的糖尿病患者围手术期胰高血糖素样肽-1受体激动剂的管理与误吸风险
Dan Med J. 2025 Apr 9;72(5):A09240629. doi: 10.61409/A09240629.

本文引用的文献

1
Semaglutide in Early Type 1 Diabetes.司美格鲁肽用于1型糖尿病早期治疗
N Engl J Med. 2023 Sep 7;389(10):958-959. doi: 10.1056/NEJMc2302677.
2
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.2021 年全球 1 型糖尿病发病率、患病率和死亡率，并预测至 2040 年：一项建模研究。
Lancet Diabetes Endocrinol. 2022 Oct;10(10):741-760. doi: 10.1016/S2213-8587(22)00218-2. Epub 2022 Sep 13.
3
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
在 ADJUNCT ONE 和 ADJUNCT TWO 随机对照试验中，根据基线特征评估利拉鲁肽在 1 型糖尿病中的疗效和安全性。
Diabetes Obes Metab. 2021 Dec;23(12):2752-2762. doi: 10.1111/dom.14532. Epub 2021 Sep 28.
4
Characteristics of adult- compared to childhood-onset type 1 diabetes.成人发病与儿童发病 1 型糖尿病的特征比较。
Diabet Med. 2020 Dec;37(12):2109-2115. doi: 10.1111/dme.14314. Epub 2020 May 21.
5
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.利拉鲁肽联合胰岛素治疗 1 型糖尿病的疗效和安全性：ADJUNCT ONE 达标随机临床试验。
Diabetes Care. 2016 Oct;39(10):1702-10. doi: 10.2337/dc16-0691. Epub 2016 Aug 9.
6
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.利拉鲁肽联合胰岛素封顶治疗 1 型糖尿病患者的疗效和安全性：ADJUNCT TWO 随机试验。
Diabetes Care. 2016 Oct;39(10):1693-701. doi: 10.2337/dc16-0690. Epub 2016 Aug 4.
7
Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes.根据诊断时的年龄和 1 型糖尿病的病程，可检测到 C-肽的流行率。
Diabetes Care. 2015 Mar;38(3):476-81. doi: 10.2337/dc14-1952. Epub 2014 Dec 17.
8
Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden.瑞典克鲁努贝里省成人及儿童1型和2型糖尿病的发病率。
Diabetes Res Clin Pract. 2008 Nov;82(2):247-55. doi: 10.1016/j.diabres.2008.07.022. Epub 2008 Sep 18.